Intratumoral Cancer Therapies Market Size to Witness Substantial Boost at a CAGR of XX% in the 7MM During the Study Period 2019-2032 | Major Companies- Merck, Lokon Pharma, Idera Pharmaceuticals, and others.

DelveInsight's Intratumoral Cancer Therapies Market report offers detailed information on current treatment practices, emerging drugs, Intratumoral Cancer Therapies market share of the individual therapies, current and forecasted Intratumoral Cancer Therapies market size from 2019 to 2032 segmented into 7MM (the USA, EU5 (the UK, Italy, Spain, France, and Germany), and Japan).

Key Takeaways from the Intratumoral Cancer Therapies Market Report
• Out of all the major cancers studied, i.e., Melanoma, Nonmelanoma skin cancer, Head and Neck Cancer, Pancreatic Cancer, Renal Cell Carcinoma, Colorectal Cancer, Breast Cancer, Brain Cancer, and Soft Tissue Sarcoma, Nonmelanoma skin cancer (NMSC) contributed to the highest number of cases in the 7MM.
• As per DelveInsight's estimates, the total NMSC incident cases in the 7MM was 774,926 in 2020.
• At present, there are only three Intratumoral approved drugs namely Imlygic (Talimogene laherparepvec/T-VEC; Amgen), Hensify (NBTXR3; Nanobiotix) and Delytact (teserpaturev/G47∆; Daiichi Sankyo). Imlygic (Amgen) is the first and only FDA-approved viral therapy that is injected directly into melanoma tumors.
• The highest Intratumoral Cancer Therapies market share is primarily dominated by the USA in the 7MM that is anticipated to soar at a CAGR of 42% by 2030.
• Key pharmaceutical and biotech companies actively engaged in the Intratumoral Cancer Therapies market space include Checkmate Pharmaceuticals, OncoSec Medical Incorporated, Merck, Istari Oncology, Replimune/ Regeneron, Philogen, Exicure, Sirnaomics, Nanobiotix, Intensity Therapeutics, NanOlogy, Lokon Pharma, DNAtrix, Treovir, Idera Pharmaceuticals, Immunovative Therapies, among others.
• The Intratumoral Cancer pipeline therapies expected to get launched in the forecasted period (2021-2030) include Vidutolimod, TAVO, CAVATAK, PVSRIPO, RP1, Daromun, Cavrotolimod, Cotsiranib, Hensify, INT230-6, Delolimogene mupadenorepvec, Intuvax, Tasadenoturev, G207, Tilsotolimod, AlloStim, and others.
• The majority of the emerging therapies are working on the principle of turning "cold" tumors to "hot" and then simultaneously targeting the tumor with immune checkpoint inhibitors.
• Several pharmaceutical companies are putting out enormous effort to shift the existing paradigm and stigma surrounding intratumoral treatments and address the current unmet needs while considering the current disadvantages associated with these medicines.

Download a PDF Sample of the Intratumoral Cancer Therapies Market Research Report @ https://www.delveinsight.com/sample-request/intratumoral-cancer-therapies-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Intratumoral Cancer Therapies Disease Overview
The cancer treatment landscape has transformed to incorporate novel therapies which mainly include chemotherapy, hormone therapy, immunotherapy, gene therapy, radiotherapy, stem cell transplant, surgery, and targeted therapy. However, there are patients who do not respond to any of the available treatment options or develop resistance to available therapies. Recently, the scientific community has developed a keen interest in Intratumoral Cancer Therapies that are immunotherapies administered directly into tumors via injections, however, they can refer to any therapy provided in close anatomical proximity to a tumor with the goal of direct uptake by tumors.

Intratumoral Cancer Therapies Indication-wise Segmentation in the 7MM
• Total Incident Cases of Selected Cancer Types (Melanoma, Nonmelanoma skin cancer, Head and Neck Cancer, Pancreatic Cancer, Renal Cell Carcinoma, Colorectal Cancer, Breast Cancer, Brain Cancer, and Soft Tissue Sarcoma)
• Target Patient Pool of Intratumoral Therapies by Cancer Types
• Treated Cases by Cancer Types

Intratumoral Cancer Therapy Market Outlook
Intratumoral (intralesional) administration of immunotherapeutics is a promising way to target local tumor immunity barriers directly. Different categories of Intratumoral Cancer Therapies in the pipeline under investigation include oncolytic viruses, monoclonal antibodies, and small molecules, and others are being investigated.

The present Intratumoral Cancer Therapy market consists of only three approved therapies, i.e., Imlygic (Talimogene laherparepvec/T-VEC; Amgen), Delytact (teserpaturev/G47∆; Daiichi Sankyo) and Hensify (NBTXR3; Nanobiotix). The first approval for an intratumoral therapy was received in 2015, wherein the United States Food and Drug Administration (US FDA) approved Imlygic (talimogene laherparepvec; T-Vec) to treat melanoma. It is a genetically modified herpes simplex virus type 1-based oncolytic immunotherapy and is the first oncolytic virus approved by the US FDA to treat unresectable melanoma recurrent after the initial surgery. Later on in 2019, the European Union (EU) approved Hensify (NBTXR3) for the treatment of patients suffering from Soft tissue sarcoma, and recently in 2021, the Japan Ministry of Health, Labour and Welfare (MHLW) granted conditional and time-limited approval to Delytact (teserpaturev) for the treatment of malignant glioma.

Find out the more information of the Intratumoral Cancer Therapies Market Dynamics Report @ https://www.delveinsight.com/sample-request/intratumoral-cancer-therapies-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Intratumoral Cancer Pipeline Therapies in Focus in the Report Analysis
Currently, the Intratumoral Cancer Therapy pipeline is rich with potential candidates majorly focused on the treatment of melanoma, head and neck cancer, Nonmelanoma skin cancer, along with some other cancers and expectations are high from Intratumoral Cancer Therapies.

Most of the emerging therapies are simultaneously targeting the tumor in tandem with immune checkpoint inhibitors.

DelveInsight's analysts estimate that out of all cancer types assessed, Melanoma is anticipated to dominate the Intratumoral Cancer Therapeutic market landscape.
• Vidutolimod (CMP-001): Checkmate Pharmaceuticals
• TAVO(tavokinogene telseplasmid): OncoSec Medical Incorporated
• CAVATAK (V937; CVA21): Merck & Co (Viralytics)
• PVSRIPO (PVS-RIPO): Istari Oncology
• RP1 (vusolimogene oderparepvec): Replimune/ Regeneron
• Daromun (Nidlegy): Philogen
• Cavrotolimod (AST-008): Exicure
• Cotsiranib (STP705): Sirnaomics
• Hensify (NBTXR3/ PEP503): Nanobiotix
• INT230-6 (Cisplatin/vinblastine): Intensity Therapeutics
• NanoPac (LSAM paclitaxel): NanOlogy
• Delolimogene mupadenorepvec (LOAd703): Lokon Pharma
• Intuvax (Ilixadencel)
• Tasadenoturev (DNX-2401): DNAtrix
• G207: Treovir
• Tilsotolimod (IMO-2125): Idera Pharmaceuticals
• AlloStim: Immunovative Therapies

Intratumoral Cancer Therapies Market Dynamics
DelveInsight's Intratumoral Cancer Therapies market analysis demonstrates that these therapies have immense potential to transform the treatment landscape by turning cold tumors into hot tumor and making their identification convenient by the immune system. However, the present understanding of Intratumoral therapies is poor and they also have faced backlash from the recent clinical trial failures at late stages; DelveInsight estimates that the future carries a promising outlook for the Intratumor Cancer Therapies market owing to potential emerging therapies, promising clinical trial results, the influx of pharma and biotech players, better R&D, and increasing healthcare expenditure.

Scope of the Intratumoral Cancer Therapies Market Report
• Coverage: 7MM
• Study Period: 2019-2032
• Key Companies: Checkmate Pharmaceuticals, OncoSec Medical Incorporated, Merck, Istari Oncology, Replimune/ Regeneron, Philogen, Exicure, Sirnaomics, Nanobiotix, Intensity Therapeutics, NanOlogy, Lokon Pharma, DNAtrix, Treovir, Idera Pharmaceuticals, AlloStim: Immunovative Therapies, and several others.
• Key Intratumoral Cancer Therapies in the Pipeline: Vidutolimod, Tavo, CAVATAK, PVSRIPO, RP1, Daromun, Cavrotolimod, Cotsiranib, Hensify, INT230-6, NanoPac, Delolimogene mupadenorepvec, Intuvax, Tasadenoturev, G207, Tilsotolimod, AlloStim, and several others.
• Intratumoral Cancer Therapies Market Segmentation: By Geography, By Intratumoral Cancer Therapies

Request a PDF Sample of the Intratumoral Cancer Therapies Market Forecast Report- https://www.delveinsight.com/sample-request/intratumoral-cancer-therapies-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of content
1. Key Insights
2. Executive Summary of Intratumoral Cancer Therapies
3. Competitive Intelligence Analysis for Intratumoral Cancer Therapies
4. Intratumoral Cancer Therapies: Market Overview at a Glance
5. Intratumoral Cancer Therapies: Disease Background and Overview
6. Patient Journey
7. Intratumoral Cancer Therapies Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Intratumoral Cancer Therapies Unmet Needs
10. Key Endpoints of Intratumoral Cancer Therapies Treatment
11. Intratumoral Cancer Therapies Marketed Products
12. Intratumoral Cancer Therapies Emerging Therapies
13. Intratumoral Cancer Therapies: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Intratumoral Cancer Therapies
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight

Do you have any query related to the Intratumoral Cancer Therapies market research report? If yes, visit here- https://www.delveinsight.com/sample-request/intratumoral-cancer-therapies-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.